ClinicalTrials.gg
RecruitingNCT06447740FAIRUpdated Aug 16, 2024

Fractional Flow Reserve-guided Stenting Versus Medical Therapy in Atherosclerosis Renal Artery Stenosis

An interventional study of Dopamine and Fractional Flow Reserve, Renal in Renal Artery Stenosis Atherosclerotic and Secondary Hypertension Renal Arterial, sponsored by Peking University First Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-16.

Sponsored by Peking University First Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 408 studies in Hypertension with a site in China — 123 open to participants now, 146 under way, 12 of them phase 3. Hypertension · China.

Planned enrollment
170th of 306
200 · median 255
Started
2024
with 29 others
No phase
144 of 408
55 open now
Primary completion
2026-06
later than 41 of 145 live
Registered
296th of 408
by date
Lead sponsor
7 of 408
Peking University First Hospital

Among the 408 studies in Hypertension with a site in China, this one is the 170th largest by planned enrollment of the 306 interventional ones that give a count, is one of 30 that started in 2024, is one of 144 with no phase, reaches primary completion later than 41 of the 145 other live ones, and was the 296th registered.

Hypertension

6,125 studies on the registry are indexed under Hypertension; 910 are open to participants now.

Browse Hypertension studies →

Open to participants now

123 of the 408 studies in Hypertension with a site in China are open now. Recruiting first, the newest first:

118 more — sign in →

All 123 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 557 Hypertension studies recruiting now, 264 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 138 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 408 studies in Hypertension with a site in China, or all of them as a file.
02

Study summary

Although randomized trials have demonstrated there is no benefit of renal-artery stenting in addition to medical therapy for patients with atherosclerosis renal artery stenosis, many patients indeed gained benefit in daily practices after stenting, such as reduction in blood pressure and recovery in renal functions. One important gap is that there is no universal standard to determine whether to stent in these patients. Fraction Flow Reserve (FFR) has been studied for many year in chronic coronary heart disease and FFR-guided revascularization strategy is known to be better than both angiography-guided revascularization and medication alone. Based on the primary finding of FAIR-pilot study (NCT05732077), FFR-guided renal artery stenting is practical.

The overall purpose of the FAIR trial is to compare the clinical outcomes and safety of FFR-guided stenting plus optimal medical treatment (OMT) versus OMT alone in patients with renal-vascular hypertensive patients.

With the 'all comers' design, participants met the inclusive/exclusive criteria will be enrolled, and hyperemic FFR induced by dopamine will be measured in all participants. If FFR is ≥0.80, patients will be treated with OMT alone and follow up. If FFR is \<0.80, participants will be randomized to stenting in the renal artery plus OMT or OMT alone on a 1:1 ratio. The blood pressure and anti-hypertensive medications will be compared before and 3 months after the procedure based on ambulatory blood pressure monitoring, all participants will be followed up for 1 year.

03

Conditions studied

  • Renal Artery Stenosis Atherosclerotic
  • Secondary Hypertension Renal Arterial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • With recorded hypertension, AND the blood pressure is not controlled (daytime mean SBP ≥135 mmHg and/or DBP ≥85 mmHg based on ABPM) on 2 or more classes of anti-hypertensive drugs;
  • Evidence of renal artery stenosis and undergoing renal artery angiography;
  • Able to follow the study protocol and provide ;
  • Renal artery angiography shows at least 1 main artery with stenosis of 50%-90%, AND the diameter is ≥ 4.0mm.

Exclusion criteria

Exclusion Criteria:

  • SBP ≥200mmHg and/or DBP ≥120mmHg at the day or randomization;
  • Fibromuscular dysplasia or other non-atherosclerotic renal artery stenosis;
  • Pregnancy or unknown pregnancy status in female of ;
  • Participation in any drug or device trial during the study period;
  • Any stroke/, OR with ≥70% stenosis of carotid artery;
  • Any major surgery, myocardial infarction or interventional therapy 30 days prior to study entry;
  • \<30%;
  • Comorbidity condition causing ≤1 year;
  • Allergy to contrast or any of the following: aspirin, clopidogrel;
  • Previous kidney transplant;
  • Previous renal artery bypass surgery or stent intervention;
  • Kidney size less than 8 cm measured by ultrasound;
  • Local lab serum Cr >3.0 mg/dl (265.2μmol/l) on the day of randomization;
  • Reference vessel size \<4 mm or >8 mm.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Stenting plus OMT with FFR <0.80

    Drug: Dopamine · Diagnostic Test: Fractional Flow Reserve, Renal · Device: Renal artery stenting

  • Placebo comparator
    OMT alone with FFR < 0.80

    Drug: Dopamine · Diagnostic Test: Fractional Flow Reserve, Renal

  • Other
    OMT alone with FFR ≥0.80

    Drug: Dopamine · Diagnostic Test: Fractional Flow Reserve, Renal

Interventions

  • A bolus dose of 50μg/kg dopamine via renal artery to induce hyperemic status

  • Diagnostic testFractional Flow Reserve, Renal

    Renal FFR will be measured based on SOP

  • DeviceRenal artery stenting

    Renal artery stenting will be implanted based on the protocol

06

What researchers measure

Primary outcomes

  1. Change in daytime mean systolic blood pressure as measured by 24-hour Ambulatory Blood Pressure Monitoring (ABPM)

    Time frame: From baseline to 3 months post-procedure

  2. Change in the composite index of antihypertensive drugs

    Change in the composite index of antihypertensive drugs. Drug Composite Index = Weight (number of classes of antihypertensive drugs) × (sum of doses)

    Time frame: From baseline to 3 months post-procedure

Secondary outcomes

  1. Change in systolic blood pressure as measured by 24-hour ABPM

    Time frame: From baseline to 3 months post-procedure

  2. Change in diastolic blood pressure as measured by 24-hour ABPM

    Time frame: From baseline to 3 months post-procedure

  3. Change in home blood pressure

    Time frame: From baseline to 3 months post-procedure

  4. Change in office blood pressure

    Time frame: From baseline to 3 months post-procedure

  5. Change in the composite index of antihypertensive drugs to reach target blood pressure

    Change in the composite index of antihypertensive drugs to reach target blood pressure. Drug Composite Index = Weight (number of classes of antihypertensive drugs) × (sum of doses)

    Time frame: From baseline to 1 year post-procedure

  6. Change in ABPM

    Time frame: From baseline to 6 months, 1 year post-procedure

  7. All-cause death

    Time frame: From baseline to 1 year post-procedure

  8. Cardiac death

    Time frame: From baseline to 1 year post-procedure

  9. Acute myocardial infarction incidence

    Based on universal definition of acute myocardial infarction

    Time frame: From baseline to 1 year post-procedure

  10. Non-fatal stroke incidence

    Based on medical records under outcome committee's judge

    Time frame: From baseline to 1 year post-procedure

  11. Rehospitalization due to heart failure incidence

    Based on medical records under outcome committee's judge

    Time frame: From baseline to 1 year post-procedure

  12. Change in serum creatinine or dialysis

    Time frame: From baseline to 1 year post-procedure

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Jun 2026, 24 months after the start.

Of 1,406 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 24 months is close to that.

Counting every sponsor, half of 1,501 studies reached it within 23 months; a quarter within 10 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2024
First posted
Jun 7, 2024
StartActual
Jun 3, 2024
Primary completionEst.
Jun 3, 2026
CompletionEst.
Apr 3, 2027
Last update
Aug 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06447740
Responsible party
Sponsor
First posted
Jun 7, 2024
Start date
Jun 3, 2024
Primary completion
Jun 3, 2026 (estimated)
Completion
Apr 3, 2027 (estimated)
Last update
Aug 16, 2024

Study contacts

Yuxi Li, MD
Contact
liyuxi@pku.edu.cn
00861083572283

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion